Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (20768)	12/7/2006 12:40:21 PM
From: Galirayo	Read Replies (1) \| Respond to of 23958

Generex Biotechnology Selects Inyx to Produce Glucose RapidSpray(TM) for Worldwide Markets Thursday December 7, 9:35 am ET NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in treating metabolic diseases via drug delivery through the inner lining of the mouth, and Inyx, Inc. (OTC Bulletin Board: IYXI - News), a specialty pharmaceutical company focused on niche drug-delivery technologies and products, announced today that the two companies have signed a letter of intent for Inyx to serve as the exclusive manufacturer of Generex's proprietary Glucose RapidSpray(TM), its new confectionary glucose oral-spray product. ADVERTISEMENT The three-year agreement, which is expected to commence in the first quarter of 2007, includes technical transfer, commercial manufacturing, packaging and supply. Inyx will be the sole producer of Glucose RapidSpray(TM) for Generex in worldwide markets, with the exceptions of Canada and the Republic of Ecuador. Glucose RapidSpray(TM) is an innovative alternative for people who require or want additional glucose in their diet. It delivers a fat-free, low-calorie glucose formulation that was developed using Generex's proprietary buccal drug-delivery technologies. The formulation is delivered via spray to the inner lining of the mouth, with no lung deposition. Glucose RapidSpray(TM) is convenient to carry and simple to use. It provides swift, effective results without large tablets to chew or messy gels to swallow. In making the announcement, Anna Gluskin, President & Chief Executive Officer of Generex, commented, "We are pleased to combine Generex's patented technologies with Inyx's drug-delivery production expertise to bring to market a more efficacious product for responding to the symptoms of low blood sugar." Jack Kachkar, M.D., Chairman of Inyx, Inc., said, "We are very pleased that Inyx has been selected for the commercial production of Glucose RapidSpray(TM), and we look forward to a long-term relationship with Generex, a new client."